Curator Dashboard

A classification system developed by the National Institute on Aging and the Alzheimer's Association that can be used to integrate and compare Alzheimer's disease (AD) research portfolios from public and private organizations supporting AD research in the US and abroad. The CADRO was constructed as a three-tier classification system organized around seven major categories: five in research and two resource-related: * Category A. Molecular Pathogenesis and Pathophysiology of Alzheimer's Disease * Category B. Diagnosis, Assessment and Disease Monitoring * Category C. Translational Research and Clinical Interventions * Category D. Epidemiology * Category E. Care, Support and Health Economics of Alzheimer's Diseases * Category F. Research Resources * Category G. Consortia and Public Private Partnerships * Category H. Alzheimer's Disease - Related Dementias Using information from project abstracts and research aims, the above categories were stratified into research topics and these were further divided into research themes. The three levels of classification are meant to enable a fine-grained portfolio analysis that can inform strategic planning and funding decisions. The CADRO was developed as a dynamic portfolio analysis tool that can be used to: (i) capture the changing landscape of AD research funded by different organizations, (ii) identify opportunities for coordination of support for AD research, and (iii) identify funding gaps as well as areas of overlap within and across organizations.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A portal to educational resources.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

A flexible, extensible and modular XML-based data exchange standard for seismological data which is intended to cover a broad range of fields.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Database that brings together funded Alzheimer's disease (AD) research supported by public and private organizations both in the US and abroad all categorized using the Common Alzheimer's Disease Research Ontology or CADRO. Launched as a joint collaboration between the National Institute on Aging (NIH) and the Alzheimer's Association, IADRP enables users the ability to assess the portfolios of major organizations (currently 30) for areas of overlap as well as areas of opportunities in which to collaborate and coordinate in a collective effort to advance AD research.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A network for supporting resting-state fMRI (R-fMRI) related studies. It connects R-fMRI researchers (as nodes) by their sharings (as edges). Through the network, ideas, comments, resources, tools, experiences, and data can be shared. Researchers (nodes) with basic neuroscience, methodological, or clinical backgrounds can connect with each other in the network. It also contains a preprint server that allows neuroscientists to share their preprints, comment on each others research and get back valuable information about their experiments from their colleagues. This is based on the arXiv model. Ultimately, the network aims to enhance collaborations among researchers, especially to translate knowledge of basic neuroscience and methodology to clinical applications (bench to bedside).

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Cancer Research UK is UK's largest charity funding cancer research. Cancer Research UK is a registered charity in England and Wales (1089464) and in Scotland (SC041666). Registered as a company limited by guarantee in England & Wales No. 4325234.

• Resource
• SciCrunch
• 16 years ago - by Anonymous

Pharmaceutical company focused on investigating experimental oral antioxidative and anti-inflammatory drugs, which dually activate the antioxidative transcription factor Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) and inhibit the pro-inflammatory transcription factor NF-B (nuclear factor kappa-light-chain-enhancer of activated B cells). The antioxidative and anti-inflammatory compounds bardoxolone methyl and RTA 408 are the lead clinical development compounds in their portfolio.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Contract research organization, clinical trial services, and pharmaceutical consulting service company. Now IQVIA after merger of Quintiles and IMS Health, Inc.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Company developing peritoneal dialysis disinfection system to improve quality of life for dialysis patient by reducing infections related to peritoneal dialysis (PD) and saving time through improved, simplified connection of PD catheters. While decreasing dependence on patient compliance, the goal is to keep patients well protected and healthy throughout the efficient dialysis process.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A biopharmaceutical company developing pharmaceuticals for patients with renal and vascular diseases. Their ongoing Phase 3 clinical trial is evaluating whether a single treatment of PRT-201 can reduce vascular access failure, one of the most serious problems experienced by patients with chronic kidney disease (CKD) undergoing hemodialysis. PRT-201 is an investigational drug that may inhibit neointimal hyperplasia, the growth of tissue inside blood vessels that can result in vessel narrowing and reduced blood flow. PRT-201 has received fast track and orphan drug designations for hemodialysis vascular access indications.In September 2019, Proteon Therapeutics merged with ArTara Therapeutics.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Healthcare company that oversees all pharmaceutical and medical device commercial activities of Otsuka Group (Otsuka) in North America. Products with emphasis on neuroscience, oncology, cardio-renal, and medical device markets.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A multi-national pharmaceutical and diagnostics company that develops, manufactures, and distributes an extensive array of diagnostics and therapeutics for a wide range of indications and conditions. They focus on production of cardiovascular products, vaccines, hormones, antibiotics, gastrointestinal products, and eye care. The company operates in the U.S., Chile, Israel, Mexico, Uruguay, and Spain. (Adapted from Wikipedia)

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Consortium formed to facilitate genome-wide association study meta-analyses and replication opportunities among multiple large and well-phenotyped longitudinal cohort studies. A bibliography of CHARGE publications is available. Its founding member cohorts include: * Age, Gene, Environment, Susceptibility Study -- Reykjavik * Atherosclerosis Risk in Communities Study * Cardiovascular Health Study * Framingham Heart Study * Rotterdam Study Additional core cohorts include: * Coronary Artery Risk Development in Young Adults * Family Heart Study * Health, Aging, and Body Composition Study * Jackson Heart Study * Multi-Ethnic Study of Atherosclerosis

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Disease-related portal with the objective to defeat neuromuscular diseases which are devastating muscle-wasting diseases. It has set itself two missions: curing neuromuscular diseases and reducing the disabilities they cause.

• Resource
• SciCrunch
• 16 years ago - by Anonymous

A non-profit registered French charity that provides a research on Alzheimer's disease and related disorders program with the following goals: * create a dynamic national and international collaborative research of the fundamental absorptions, * densify the network of public and private researchers with an attractive policy * install infrastructure basic, clinical and laboratory performing research * promote interaction with the health industries to reduce development time. At the national level the Foundation has implemented measures Research Plan, through: * animation fabric French medical and scientific research, * coordination of research initiatives * the implementation of actions, * support for specific projects. Internationally, the Foundation is at the origin of an international mobilization of researchers, initiated during the French Presidency of the European Union. Called Joint Programming, this pilot initiative involves 23 countries will coordinate their efforts at European level research on neurodegenerative diseases, especially Alzheimer's disease.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Public research university in Beersheba, Israel. Ben-Gurion University of the Negev has five campuses: the Marcus Family Campus, Beer Sheva; the David Bergmann Campus, Beer Sheva; the David Tuviyahu Campus, Beer Sheva; the Sede Boqer Campus, and Eilat Campus.

• Organization
• SciCrunch
• 12 years ago - submitted by Andrea Stagg

An Antibody supplier

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Consortium to discover and map the genes that contribute to Alzheimer's disease and completely understand the role inheritance plays. To achieve this goal, they will work to identify all the genes that contribute to the risk of developing this disease. Investigators will have access to combined genetic data from a large number of Alzheimer's disease subjects and compare it to genetic data from an equally large number of elderly people who do not have Alzheimer's. In the initial phase of the work, more than 20,000 people with Alzheimer's and about 20,000 healthy elderly subjects will be compared. As the study progresses, 10,000 additional people with Alzheimer's and the same number of healthy elderly subjects will be added to the study. The subjects for these studies come from different Alzheimer research project locations across Europe, the UK, the US, and Canada. Data is available from their 2014 publication in Translational Psychiatry at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944635/ (http://www.ncbi.nlm.nih.gov/pubmed/24495969) Currently, there is no public access to the raw individual level genetic data because of privacy considerations. Researchers working with US cohorts deposit data in the database of genotypes and phenotypes (dbGaP), where it is available to all researchers who can show that they are able to guarantee the security of the data. After scanning the DNA of over 74,000 patients and controls from 15 countries, the IGAP consortium reported 11 new regions of the genome involved in late-onset Alzheimer's disease. IGAP published its results in Nature Genetics on October 27, http://www.ncbi.nlm.nih.gov/pubmed/24162737

• Organization
• Consortia-pedia, a FasterCures Project
• 12 years ago - by Anonymous

Consortium that created the capability to detect Adverse Drug Response (ADR) signals by creating the infrastructure for large-scale monitoring of drug safety using electronic health records (EHR). The platform leverages EHR''''s comprising demographics, drug use and clinical data of over 30 million patients from several European countries. Special attention was given to patient groups that are not routinely involved in clinical trials, for ethical or practical reasons (e.g. pregnant women, elderly people, people using many drugs simultaneously, and children). This project also studies and compares a number of different techniques that all aim to detect unexpected or disproportional rates of events. The algorithms that they studied originate not only from the field of (pharmaco)epidemiology, but also from fields such as bio-terrorism, machine learning, and classical signal detection. EU-ADR specific objectives are: To detect events, To relate these events to drugs, To develop hypothesis that explain adverse events, To detect adverse events earlier, and To avoid false positives. The web-based platform is available at https://bioinformatics.ua.pt/euadr/ EU-ADR has contributed to the ability to conduct better drug safety studies based on the re-use of healthcare data. By facilitating the early detection of adverse drug reactions, but also providing key information on populations at risk, potential drug interactions, potential underlying mechanisms and intervening pathways in adverse events, etc., the project will allow for improved and more complete information to be available for drug and healthcare delivery, leading to increased patient safety and its associated cost savings. The EU-ADR system can be considered as a complementary tool to already existing pharamcovigilance systems. Should the system be widespread in the long term, it has the potential to contribute to the development of future electronic health record systems, insofar as the expected benefits of these IT tools are only fully attainable when EHRs develop themselves in consistency, richness and formats that allow them to be subject of such tools. In anticipation, EU-ADR has been designed to be modular and scalable, so that different EHR databases (other than those participating in the Consortium) can be progressively enlisted in the future, adopt the software for data extraction and therefore become susceptible of exploitation by the system, for maximum global effect.

• Organization
• Consortia-pedia, a FasterCures Project
• 12 years ago - by Anonymous

Consortium formed to improve global health by overcoming obstacles to the development and implementation of biomedical innovation. CBI provides a safe and transparent environment for collaborative research among industry, academia, and government, and draws on the expertise of the Massachusetts Institute of Technology''''s (MIT) Schools of Engineering, Science, and Management, as well as the Harvard-MIT Division of Health Sciences and Technology (HST). The center manages several consortia addressing a variety of challenges in the global biomedical industry by developing, testing, and disseminating new knowledge and tools designed for real world application through the following programs: the Biomanufacturing Program (BioMAN), the Consortium on Adventitious Agents in Biomanufacturing (CAACB), and New Drug Development Paradigms (NEWDIGS). The consortia managed by CBI include: * Biomanufacturing (BioMAN): a collaborative research and educational program in biotherapeutic manufacturing. The objective is to develop new knowledge, science, technologies and strategies that advance the manufacture and global delivery of high quality biopharmaceuticals. BioMAN activities bring together thought leaders from industry, the government/FDA and academia and involve faculty from across the Schools of Science, Engineering and Management at MIT * Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB): Their mission is to develop a comprehensive understanding of adventitious agents encountered in biomanufacturing, the sources of such agents, and a systematic, risk-based analysis of the most effective strategies and technologies to prevent contamination. * NEW Drug Development ParaDIGmS (NEWDIGS): focuses on transforming the current global pharmaceutical innovation ecosystem to more reliably and sustainably deliver new, better, affordable drugs to the right patients faster. System re-engineering projects are designed and executed with input from industry; regulators from US, Europe, Singapore, and Canada; payers and health technology assessment officials; providers, patients, and academic researchers from MIT, Harvard and other leading academic institutions.

• Organization
• Consortia-pedia, a FasterCures Project
• 12 years ago - by Anonymous